ArticleJournal of diabetes science and technology2021
Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology.
Article in Journal of diabetes science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Equity of Continuous Glucose Monitoring in Children and Young People With Type 1 Diabetes: A Systematic Review.Pediatric diabetes · 2025Pooled it
- Use of continuous glucose monitoring systems in pediatric patients in the perioperative environment: Challenges and machine learning opportunities.World journal of clinical pediatrics · 2025Review
- Mapping Barriers and Interventions to Diabetes Self-Management in Latino Youth: A Scoping Review.Children (Basel, Switzerland) · 2025Review
- Race and ethnic disparities in insulin pump and continuous glucose monitor use between 2017 and 2024: a systematic review with a focus on health equity.Journal of health equity · 2025Article
- Insights from Team Clinic: A Person-Centered Virtual Peer Group Care Model Adapted for Marginalized and Historically Excluded Youth with Type 1 Diabetes (T1D).Children (Basel, Switzerland) · 2024Article
- Continuous Glucose Monitor: Reclaiming Type 2 Diabetes Self-efficacy and Mitigating Disparities.Journal of the Endocrine Society · 2024Article
- Technology and health inequities in diabetes care: How do we widen access to underserved populations and utilize technology to improve outcomes for all?Diabetes, obesity & metabolism · 2024Article
- Benchmarking Diabetes Technology Use Among 21 U.S. Pediatric Diabetes Centers.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Expanding the use of patient-reported outcomes (PROs): Screening youth with type 1 diabetes from underrepresented populations.Journal of diabetes and its complications · 2023Article
- Endocrine Health and Health Care Disparities in the Pediatric and Sexual and Gender Minority Populations: An Endocrine Society Scientific Statement.The Journal of clinical endocrinology and metabolism · 2023Article
- Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes.Diabetes care · 2023Article
- Roadmap to Continuous Glucose Monitoring Adoption and Improved Outcomes in Endocrinology: The 4T (Teamwork, Targets, Technology, and Tight Control) Program.Diabetes spectrum : a publication of the American Diabetes Association · 2023Article
- Clinically Serious Hypoglycemia Is Rare and Not Associated With Time-in-range in Youth With New-onset Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2021Article
- Provider Implicit Bias Impacts Pediatric Type 1 Diabetes Technology Recommendations in the United States: Findings from The Gatekeeper Study.Journal of diabetes science and technology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe determined the uptake rate of continuous glucose monitors (CGMs) and examined associations of clinical and demographic characteristics with CGM use among patients with type 1 diabetes covered by Colorado Medicaid during the first two years of CGM coverage with no out-of-pocket cost.
methodWe retrospectively reviewed data from 892 patients with type 1 diabetes insured by Colorado Medicaid (Colorado Health Program [CHP] and CHP+, Colorado Medicaid expansion). Demographics, insulin pump usage, CGM usage, and hemoglobin A1c (A1c) were extracted from the medical record. Data downloaded into CGM software at clinic appointments were reviewed to determine 30-day use prior to appointments. Subjects with some exposure to CGM were compared to subjects never exposed to CGM, and we examined the effect of CGM use on glycemic control.
resultsTwenty percent of subjects had some exposure to CGM with a median of 22 [interquartile range 8, 29] days wear. Sixty one percent of CGM users had >85% sensor wear. Subjects using CGM were more likely to be younger (
conclusionPediatric Medicaid patients successfully utilized CGM. Expansion of Medicaid coverage for CGM may help improve glycemic control and lessen disparities in clinical outcomes within this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.